BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced the pricing of a secondary offering of 5,000,000 shares of its common stock to be sold by existing shareholder KKR Genetic Disorder L.P.. BridgeBio is not issuing any shares in this transaction and will not receive any offering proceeds.

The offering is expected to close on August 17, 2026, subject to customary closing conditions. William Blair, Goldman Sachs & Co. LLC and KKR Capital Markets LLC are acting as joint book-running managers. The shares are being offered under an automatic shelf registration statement on Form S-3ASR filed with the SEC on July 24, 2026.

Market Context

The prior offering record was 0% and -2.11% over 24 hours, giving context for this transaction. The ...

Analysis

The prior offering record was 0% and -2.11% over 24 hours, giving context for this transaction. The company receives no proceeds, while the active resale shelf and net-selling insider activity warrant attention.

Key Figures

Shares offered: 5,000,000 shares Expected closing date: August 17, 2026 Shelf effectiveness date: July 24, 2026 +1 more

4 metrics

Shares offered 5,000,000 shares Secondary offering by KKR Genetic Disorder L.P.

Expected closing date August 17, 2026 Subject to customary closing conditions

Shelf effectiveness date July 24, 2026 Automatic Form S-3ASR registration statement

SEC file number 333-297701 Automatic shelf registration statement

Previous Offering Reports

2 past events · Latest: Jan 16 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 16	Convertible notes	Neutral	+0.0%	Convertible notes priced to prefund repayment and support general corporate purposes
Jan 14	Proposed notes	Negative	-2.1%	Proposed convertible notes included potential share issuance and concurrent share repurchases

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two tag-matched offering events were followed by flat or negative 24-hour reactions, with no positive reaction recorded.

Key Terms

secondary offering, selling stockholder, automatic shelf registration statement, s-3asr

4 terms

secondary offering financial

"announced today the pricing of a secondary offering of 5,000,000 shares"

A secondary offering is when a company sells new shares of its stock to the public after its initial sale. This allows existing shareholders or the company itself to raise additional money. For investors, it can impact the stock’s price by increasing the total number of shares available, which may influence the stock’s value and how the market perceives the company’s financial health.

View in glossary

selling stockholder financial

"shares of its common stock by the selling stockholder KKR Genetic Disorder L.P."

A selling stockholder is an individual or entity that owns shares of a company's stock and chooses to sell some or all of those shares to others. This often occurs when the owner wants to cash in on their investment or reduce their stake. For investors, understanding who the selling stockholder is can provide insights into potential changes in the company's ownership or market activity.

automatic shelf registration statement regulatory

"offered pursuant to an automatic shelf registration statement on Form S-3ASR"

An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.

s-3asr regulatory

"an automatic shelf registration statement on Form S-3ASR"

A Form S-3ASR is a pre-approved registration that lets an eligible public company load a shelf of securities it may sell later without repeating a full regulatory review each time. Think of it like a pre-authorized credit line for issuing stocks or bonds: it gives the company fast, flexible access to raise money, which matters to investors because it can signal financial readiness but also means potential share dilution or swift changes in capital structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership

PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering. The offering is expected to close on August 17, 2026, subject to customary closing conditions.

William Blair, Goldman Sachs & Co. LLC and KKR Capital Markets LLC are acting as joint book-running managers for the offering.

The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-297701) that was previously filed by the Company with the Securities and Exchange Commission (the “SEC”) and automatically became effective upon filing on July 24, 2026.

A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. A copy of the prospectus supplement and accompanying prospectus can be obtained, when available, by contacting William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687 or by email at prospectus@williamblair.com; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; KKR Capital Markets LLC, 30 Hudson Yards, Suite 7500, NY, NY 10001; or by accessing the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described above, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market.

BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the SEC on August 10, 2026 and our other filings with the SEC. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

FAQ

What is included in BridgeBio Pharma (BBIO)'s August 2026 secondary offering?

BridgeBio’s August 2026 secondary offering covers 5,000,000 existing common shares sold by KKR Genetic Disorder L.P. According to BridgeBio, the company itself is not selling any shares and will not receive proceeds, making this a shareholder liquidity event rather than a capital raise.

Is BridgeBio Pharma (BBIO) issuing new shares in the August 2026 secondary offering?

No, BridgeBio is not issuing new shares in this offering. According to BridgeBio, all 5,000,000 shares are being sold by the existing shareholder KKR Genetic Disorder L.P., so the company will not receive any proceeds from the transaction.

When is the BridgeBio Pharma (BBIO) secondary offering expected to close?

The secondary offering is expected to close on August 17, 2026. According to BridgeBio, the closing remains subject to customary closing conditions typically seen in underwritten secondary equity offerings managed by investment banks.

Who is selling shares in the August 2026 BridgeBio Pharma (BBIO) secondary offering?

The selling stockholder is KKR Genetic Disorder L.P.. According to BridgeBio, this entity is offering 5,000,000 shares of BridgeBio common stock, while the company itself is not participating as a seller in the transaction.

Which banks are managing BridgeBio Pharma (BBIO)'s August 2026 secondary offering?

The joint book-running managers are William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC. According to BridgeBio, these institutions are overseeing the offering of 5,000,000 existing shares under an effective automatic shelf registration statement.

How can investors access the prospectus for BridgeBio Pharma (BBIO)'s secondary offering?

Investors can access the prospectus on the SEC’s website at www.sec.gov. According to BridgeBio, copies may also be requested from William Blair, Goldman Sachs & Co. LLC, or KKR Capital Markets LLC via their respective prospectus departments and contact details.